RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom's macroglobulinemia.
OBJECTIVES: * Determine the objective response in patients with Waldenstrom's macroglobulinemia treated with alemtuzumab. * Determine the time to treatment failure in patients treated with this drug. * Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive alemtuzumab IV over 2 hours on days 1, 3, and 5 of weeks 1-6 (course 1) in the absence of disease progression or unacceptable toxicity. Patients with a complete response undergo observation. Patients with stable disease or a minor or partial response receive an additional course of alemtuzumab, administered as in course 1, on weeks 7-12. Patients are followed every 6 months for 2 years. PROJECTED ACCRUAL: A total of 13-27 patients will be accrued for this study.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States
Rocky Mountain Cancer Centers - Denver Midtown
Denver, Colorado, United States
Objective response
Time to treatment failure
Toxicity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, United States
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Long Island Jewish Medical Center
New Hyde Park, New York, United States
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
...and 5 more locations